**5. The need for screening and screening methods for RBD**

PSG is clearly necessary for establishing the diagnosis of RBD, but the procedure requires appropriate monitoring equipment, including time synchronized video recordings, specially trained technologists, bed availability in a sleep laboratory, and clinicians who can interpret the data. The procedure is costly, especially for patients with limited insurance coverage.

Subjects must be willing and able to sleep in a sleep laboratory and undergo monitoring. Some patients with coexisting neurologic disorders are too cognitively or physically impaired to tolerate and undergo an adequate study, are too uncooperative to permit all of the monitoring equipment to remain in place, are at risk for falls during the night, or are institutionalized. RBD cannot be accurately assessed in the home. Due to the limited number of sleep disorder centers in many countries, PSG is not possible even when clearly medically warranted. As it is impractical to perform PSG in large numbers of subjects in epidemiologic studies of sleep disorders, the availability of a simple, short, reliable, and accurate measure to screen for the presence of various sleep disorders would be highly valuable (Boeve, 2010a).

A recent study suggested that a clinical interview by expert clinicians could provide good sensitivity (100%) and specificity (99.6%) in diagnosing RBD in non-PD patients (Eisensehr et al, 2001). The interobserver reliability of ICSD-R criteria for RBD was also found to be substantial (Bologna, Genova, Parma and Pisa Universities group for the study of REM sleep Behaviour Disorder (RBD) in Parkinson's Disease, 2003). Nevertheless, conducting a useful clinical interview may require considerable expertise, training, time and resources. In addition, waiting times might be long for and access limited to clinical and PSG assessments in some medical settings. Hence, an easily applicable questionnaire may be considered as a supplemental assessment tool in clinical practice to provide a quick and accurate appraisal of RBD symptoms in order to prioritize assessment and intervention.

We describe RBD screening questionnaires such as the Mayo Sleep Questionnaire (MSQ), RBDSQ (English/German version and Japanese version) and RBDQ-HK.

#### **5.1 Mayo sleep questionnaire**

RBD is a parasomnia that can develop in otherwise neurologically-normal adults as well as in those with a neurodegenerative disease. Confirmation of RBD requires PSG. A simple screening measure for RBD is desirable for clinical and research purposes. Boeve et al. developed the Mayo Sleep Questionnaire (MSQ), a 16-item measure to screen for the presence of RBD, periodic legs movement disorder (PLMD), restless legs syndrome (RLS), sleepwalking, OSAS and sleep-related leg cramps (Boeve, 2010a; Boeve et al., 2002a, 2002b, 2010b, 2011). The data presented herein refer to the primary question on RBD (Question 1); if the primary question is answered affirmatively, subquestions are asked (subquestions 1be) as shown in Table 4.

184 Sleep Disorders

hours after sleep onset. In contrast, sleepwalking and sleep terror episodes often emerge within two hours after sleep onset, are not usually associated with rapid alertness, and are rarely associated with dreaming in children. Adults can have associated dreaming, but it is

Severe OSAS and nocturnal epilepsy may mimic the symptoms of RBD. Patients with severe OSAS may present with unpleasant dreams and dream-enacting behaviors (Iranzo & Santamaria, 2005). Continuous positive airway pressure (CPAP) therapy can eliminate abnormal nocturnal behaviors. Sleep-related seizures usually present with repetitive

When a diagnostic clarification is necessary, particularly when the risk for injury is high, the behaviors occur at any time of the night, other features suggesting an evolving neurodegenerative are present, or loud snoring and observed apnea suggestive of OSA are

PSG is clearly necessary for establishing the diagnosis of RBD, but the procedure requires appropriate monitoring equipment, including time synchronized video recordings, specially trained technologists, bed availability in a sleep laboratory, and clinicians who can interpret the data. The procedure is costly, especially for patients with limited insurance coverage. Subjects must be willing and able to sleep in a sleep laboratory and undergo monitoring. Some patients with coexisting neurologic disorders are too cognitively or physically impaired to tolerate and undergo an adequate study, are too uncooperative to permit all of the monitoring equipment to remain in place, are at risk for falls during the night, or are institutionalized. RBD cannot be accurately assessed in the home. Due to the limited number of sleep disorder centers in many countries, PSG is not possible even when clearly medically warranted. As it is impractical to perform PSG in large numbers of subjects in epidemiologic studies of sleep disorders, the availability of a simple, short, reliable, and accurate measure to screen for the

A recent study suggested that a clinical interview by expert clinicians could provide good sensitivity (100%) and specificity (99.6%) in diagnosing RBD in non-PD patients (Eisensehr et al, 2001). The interobserver reliability of ICSD-R criteria for RBD was also found to be substantial (Bologna, Genova, Parma and Pisa Universities group for the study of REM sleep Behaviour Disorder (RBD) in Parkinson's Disease, 2003). Nevertheless, conducting a useful clinical interview may require considerable expertise, training, time and resources. In addition, waiting times might be long for and access limited to clinical and PSG assessments in some medical settings. Hence, an easily applicable questionnaire may be considered as a supplemental assessment tool in clinical practice to provide a quick and accurate appraisal

We describe RBD screening questionnaires such as the Mayo Sleep Questionnaire (MSQ),

RBD is a parasomnia that can develop in otherwise neurologically-normal adults as well as in those with a neurodegenerative disease. Confirmation of RBD requires PSG. A simple screening measure for RBD is desirable for clinical and research purposes. Boeve et al.

present, PSG with simultaneous video monitoring is warranted (Boeve, 2010a).

**5. The need for screening and screening methods for RBD**

presence of various sleep disorders would be highly valuable (Boeve, 2010a).

of RBD symptoms in order to prioritize assessment and intervention.

**5.1 Mayo sleep questionnaire**

RBDSQ (English/German version and Japanese version) and RBDQ-HK.

usually more fragmentary and more limited than RBD dreams.

stereotypical behaviors.

Table 4. Primary question on RBD in the Mayo Sleep Questionnaire (MSQ) (from the website: http://www.mayoclinic.org/pdfs/MSQ-copyrightfinal.pdf.)

Among the community-dwelling elderly, the MSQ has high sensitivity (100%) and specificity (95%) for diagnosis of RBD and was particularly specific for RBD in the absence of an OSA feature (Boeve, 2010b).

Boeve et al. also assessed the validity of the MSQ by comparing the responses of patients' bed partners with the findings (REM sleep without atonia) on PSG. The study subjects were 176 individuals (150 males; median age 71 years (range 39-90)) with the following clinical diagnoses: normal (n=8), mild cognitive impairment (n=44), Alzheimer's disease (n=23), dementia with Lewy bodies (n=74), and other dementia and/or parkinsonian syndromes (n=27). Sensitivity and specificity for question 1 on the MSQ for PSG-proven RBD were 98% and 74%, respectively. They concluded that the MSQ has adequate sensitivity and specificity for the diagnosis of RBD among aged subjects with cognitive impairment and/or parkinsonism (Boeve et al, 2011).

#### **5.2 RBDSQ**

Stiasny-Kolster et al. in 2007 developed the original German/English RBD Screening Questionnaire (RBDSQ) (Stiasny-Kolster et al., 2007). The RBDSQ is a 10-item patient selfrating instrument that assesses sleep behavior with short questions that have to be answered by either "yes" or "no" by the patient. Since patients do not always have a long-time companion, the bed partner's input was encouraged but not required. Items 1 to 4 address the frequency and content of dreams and their relationship to nocturnal movements and

Screening Methods for REM Sleep Behavior Disorder 187

for RBDSQ-J items, which may improve the accuracy of the questionnaire. The RBDSQ-J has high sensitivity, specificity, and reliability and would be applicable as a screening method for iRBD in an elderly Japanese population. Early-onset patients (≦50 years) were reported to have significantly more past and present psychiatric diagnoses and antidepressant usage than late-onset patients (>50 years) (Teman et al., 2009). It may be necessary to validate the

Nomura et al. evaluated the usefulness of the RBDSQ-J among patients with PD (Nomura et al., 2011). A total score of 6 points on the RBDSQ-J represented the best cut-off value for detecting RBD. This cut-off value for RBD secondary to PD was approximately 1 point higher than that reported for iRBD in studies performed by Stiasny-Kolster et al. and Miyamoto et al. However, the cut-off value with the RBDSQ-J for PD patients would become equal to the above-indicated value for iRBD patients if item 10 were removed. Nomura et al. showed that the RBDSQ-J may be useful for detecting RBD among a PD population regardless of the RBD symptoms. In addition, positivity for item 6.1 might

The existing RBD questionnaires may overlook the prevalence, frequency and severity of the clinical symptoms. There remains an obstacle for physicians to quantitatively observe and monitor treatment progress in clinical settings without the availability of timely PSG. Screening instruments for diagnosis of RBD are limited and there are none for quantifying the severity of the disease. Li et al. developed and validated a 13-item self-reported RBD questionnaire for diagnostic and monitoring purposes (Li et al., 2010). The patient always answered and the bed partner sometimes also answered in addition to the patient. Items 1-5 (Q1-Q5) were pertinent to patients' dreams and nightmares and the last eight items (Q6-Q13) elicited information on the typical behavioral consequences as a result of patients' dream enactments. Each item assesses two scales: lifetime occurrence and recent 1-yr frequency (5 point scale: 3 times or above per week; 1-2 times per week; once or a few times per month; once or few times per year; none). Scores are weighted in 7/13 questions according to the clinical importance of the behavioral manifestations of RBD. Scores range from 0-100. In a study to validate the instrument, 107 PSG-confirmed RBD patients (mean age 62.5 y) with the diagnosis of cryptogenic RBD, symptomatic RBD (PD, dementia, PD with dementia, narcolepsy), RBD-like disorder) and 107 controls (mean age 55.3 y) participated. The best RBDQ-HK cut-off score for RBD detection was 18-19, with 82% sensitivity, 87% specificity, and 86% positive predictive value; there was high test-retest reliability. Among the RBD cases, the scores of RBDQ-HK based on patients' self-reports were slightly lower compared to those provided by both patients and their relatives (e.g., bed partner)[self-report: 40.56(21.26) vs. self and relatives: 54.89(17.34), *p*=0.05]. The RBDQ-HK can be completed by patients with or without other informants such as a bed partner. However, abnormal nocturnal behaviors can go unnoticed in some RBD cases (e.g., when there is no assault or injury to self or bed partner), making the sensitivity of the RBDQ-HK different between those living and sleeping on their own and those living and sleeping with others. Hence, input on RBDQ-HK from relatives of patients is encouraged as it may enhance accuracy of the diagnosis and provide a better appraisal of

represent a key criterion for analyzing populations with non-violent RBD.

RBDSQ-J in early-onset patients.

**5.4 RBDQ-HK** 

treatment progress.

behavior. Item 5 asks about self-injuries and injuries of the bed partner. Item 6 consists of four subitems that assess nocturnal motor behavior more specifically, e.g., questions about nocturnal vocalization, sudden limb movements, complex movements, or items around the bed that fell down. Items 7 and 8 deal with nocturnal awakenings. Item 9 focuses on disturbed sleep in general and item 10 on the presence of any neurological disorder. The maximum total score for the RBDSQ is 13 points. The RBDSQ was applied to 54 RBD patients (mean age 53.7 years, range 19-79) who had been clinically diagnosed with iRBD (n=19), narcolepsy (n=33), early PD (n=2)) and 160 patients without RBD (age 50.8 years, range 20-83) who had been diagnosed as having RLS (n=73), narcolepsy (n=27), OSAS (n=21), hypersomnia (n=10), PLMD (n=8), insomnia (n=4), sleepwalking (n=4), epilepsy (n=3), nightmares (n=1), sleep bruxisum (n=1), or depression. (n=1). Also studied were 133 healthy subjects (mean age 46.9 years, range 20-72). Using a cut-off value of five points on the RBDSQ as a discriminatory variable, the questionnaire revealed a sensitivity of 96% and a specificity of 56%, correctly diagnosing 66% of subjects with sleep disorders. They mentioned that the lower specificity might be due to the fact that most of their control patients had sleep disturbances or neurological disorders that are known to be associated with periodic leg movements, e.g., RLS, PLMD, narcolepsy, and OSAS. This selection bias predisposed to positive answers for items that are related either to limb movements such as items 4, 5, 6.2, and 7 or to the presence of sleep and/or neurologic disorders such as for items 9 and 10, leading to higher RBDSQ total scores and thus to a lower specificity. Considering its high sensitivity, the RBDSQ represents an adequate tool to detect subjects with RBD. In subjects without additional neurologic or sleep disorders, the specificity was high, but in patients with either neurologic diseases or sleep disorders, the specificity is poorer but acceptable. The authors demonstrated the RBDSQ might be applied within a stepwise diagnostic process (questionnaire, interview, PSG).

#### **5.3 RBDSQ-J**

We developed a Japanese version of the RBDSQ (RBDSQ-J) after obtaining approval from the patent owner and investigated its validity and reliability (Miyamoto et al., 2009). The RBDSQ-J was administered to 52 consecutive patients with iRBD diagnosed according to criteria in the ICSD-2 (mean age 66.4 years; 36 males, 16 females), 55 consecutive OSAS patients who had responded well to CPAP therapy (mean age 63.1 years; 44 males, 11 females) after a diagnosis of RBD was ruled out by history and PSG and 65 apparently healthy subjects (mean age 64.6 years; 37 males, 28 females).

The mean RBDSQ-J scores for the iRBD group, the OSAS group and the healthy subjects were 7.5, 1.9, and 1.6 points, respectively. Sensitivity and specificity using a cut-off of 4.5 were high in differentiating the iRBD group from healthy subjects or the OSAS group. An RBDSQ-J score cut-off of 5.0 was considered useful for differentiating the iRBD group from the healthy subjects or the OSAS group. Cronbach's alpha for the entire RBDSQ-J was 0.866. The RBDSQ-J score had no correlation with the duration of RBD (mean disease duration in the iRBD group from symptom onset was 4.6 years, range 0.2 to 18 years). Answers to some items varied or had lower sensitivity. For example, for items 5, 6.2, and 6.3 a bed partner would be needed to provide answers, and the situations referred to in items 6.4 and 8 were often obscure. In evaluation of reliability, items that enlarged the kappa coefficient were 1, 2, 5 and 6.1 for iRBD. It can be proposed that future evaluations should use weighted scores for RBDSQ-J items, which may improve the accuracy of the questionnaire. The RBDSQ-J has high sensitivity, specificity, and reliability and would be applicable as a screening method for iRBD in an elderly Japanese population. Early-onset patients (≦50 years) were reported to have significantly more past and present psychiatric diagnoses and antidepressant usage than late-onset patients (>50 years) (Teman et al., 2009). It may be necessary to validate the RBDSQ-J in early-onset patients.

Nomura et al. evaluated the usefulness of the RBDSQ-J among patients with PD (Nomura et al., 2011). A total score of 6 points on the RBDSQ-J represented the best cut-off value for detecting RBD. This cut-off value for RBD secondary to PD was approximately 1 point higher than that reported for iRBD in studies performed by Stiasny-Kolster et al. and Miyamoto et al. However, the cut-off value with the RBDSQ-J for PD patients would become equal to the above-indicated value for iRBD patients if item 10 were removed. Nomura et al. showed that the RBDSQ-J may be useful for detecting RBD among a PD population regardless of the RBD symptoms. In addition, positivity for item 6.1 might represent a key criterion for analyzing populations with non-violent RBD.

#### **5.4 RBDQ-HK**

186 Sleep Disorders

behavior. Item 5 asks about self-injuries and injuries of the bed partner. Item 6 consists of four subitems that assess nocturnal motor behavior more specifically, e.g., questions about nocturnal vocalization, sudden limb movements, complex movements, or items around the bed that fell down. Items 7 and 8 deal with nocturnal awakenings. Item 9 focuses on disturbed sleep in general and item 10 on the presence of any neurological disorder. The maximum total score for the RBDSQ is 13 points. The RBDSQ was applied to 54 RBD patients (mean age 53.7 years, range 19-79) who had been clinically diagnosed with iRBD (n=19), narcolepsy (n=33), early PD (n=2)) and 160 patients without RBD (age 50.8 years, range 20-83) who had been diagnosed as having RLS (n=73), narcolepsy (n=27), OSAS (n=21), hypersomnia (n=10), PLMD (n=8), insomnia (n=4), sleepwalking (n=4), epilepsy (n=3), nightmares (n=1), sleep bruxisum (n=1), or depression. (n=1). Also studied were 133 healthy subjects (mean age 46.9 years, range 20-72). Using a cut-off value of five points on the RBDSQ as a discriminatory variable, the questionnaire revealed a sensitivity of 96% and a specificity of 56%, correctly diagnosing 66% of subjects with sleep disorders. They mentioned that the lower specificity might be due to the fact that most of their control patients had sleep disturbances or neurological disorders that are known to be associated with periodic leg movements, e.g., RLS, PLMD, narcolepsy, and OSAS. This selection bias predisposed to positive answers for items that are related either to limb movements such as items 4, 5, 6.2, and 7 or to the presence of sleep and/or neurologic disorders such as for items 9 and 10, leading to higher RBDSQ total scores and thus to a lower specificity. Considering its high sensitivity, the RBDSQ represents an adequate tool to detect subjects with RBD. In subjects without additional neurologic or sleep disorders, the specificity was high, but in patients with either neurologic diseases or sleep disorders, the specificity is poorer but acceptable. The authors demonstrated the RBDSQ might be applied within a

We developed a Japanese version of the RBDSQ (RBDSQ-J) after obtaining approval from the patent owner and investigated its validity and reliability (Miyamoto et al., 2009). The RBDSQ-J was administered to 52 consecutive patients with iRBD diagnosed according to criteria in the ICSD-2 (mean age 66.4 years; 36 males, 16 females), 55 consecutive OSAS patients who had responded well to CPAP therapy (mean age 63.1 years; 44 males, 11 females) after a diagnosis of RBD was ruled out by history and PSG and 65 apparently

The mean RBDSQ-J scores for the iRBD group, the OSAS group and the healthy subjects were 7.5, 1.9, and 1.6 points, respectively. Sensitivity and specificity using a cut-off of 4.5 were high in differentiating the iRBD group from healthy subjects or the OSAS group. An RBDSQ-J score cut-off of 5.0 was considered useful for differentiating the iRBD group from the healthy subjects or the OSAS group. Cronbach's alpha for the entire RBDSQ-J was 0.866. The RBDSQ-J score had no correlation with the duration of RBD (mean disease duration in the iRBD group from symptom onset was 4.6 years, range 0.2 to 18 years). Answers to some items varied or had lower sensitivity. For example, for items 5, 6.2, and 6.3 a bed partner would be needed to provide answers, and the situations referred to in items 6.4 and 8 were often obscure. In evaluation of reliability, items that enlarged the kappa coefficient were 1, 2, 5 and 6.1 for iRBD. It can be proposed that future evaluations should use weighted scores

stepwise diagnostic process (questionnaire, interview, PSG).

healthy subjects (mean age 64.6 years; 37 males, 28 females).

**5.3 RBDSQ-J**

The existing RBD questionnaires may overlook the prevalence, frequency and severity of the clinical symptoms. There remains an obstacle for physicians to quantitatively observe and monitor treatment progress in clinical settings without the availability of timely PSG. Screening instruments for diagnosis of RBD are limited and there are none for quantifying the severity of the disease. Li et al. developed and validated a 13-item self-reported RBD questionnaire for diagnostic and monitoring purposes (Li et al., 2010). The patient always answered and the bed partner sometimes also answered in addition to the patient. Items 1-5 (Q1-Q5) were pertinent to patients' dreams and nightmares and the last eight items (Q6-Q13) elicited information on the typical behavioral consequences as a result of patients' dream enactments. Each item assesses two scales: lifetime occurrence and recent 1-yr frequency (5 point scale: 3 times or above per week; 1-2 times per week; once or a few times per month; once or few times per year; none). Scores are weighted in 7/13 questions according to the clinical importance of the behavioral manifestations of RBD. Scores range from 0-100. In a study to validate the instrument, 107 PSG-confirmed RBD patients (mean age 62.5 y) with the diagnosis of cryptogenic RBD, symptomatic RBD (PD, dementia, PD with dementia, narcolepsy), RBD-like disorder) and 107 controls (mean age 55.3 y) participated. The best RBDQ-HK cut-off score for RBD detection was 18-19, with 82% sensitivity, 87% specificity, and 86% positive predictive value; there was high test-retest reliability. Among the RBD cases, the scores of RBDQ-HK based on patients' self-reports were slightly lower compared to those provided by both patients and their relatives (e.g., bed partner)[self-report: 40.56(21.26) vs. self and relatives: 54.89(17.34), *p*=0.05]. The RBDQ-HK can be completed by patients with or without other informants such as a bed partner. However, abnormal nocturnal behaviors can go unnoticed in some RBD cases (e.g., when there is no assault or injury to self or bed partner), making the sensitivity of the RBDQ-HK different between those living and sleeping on their own and those living and sleeping with others. Hence, input on RBDQ-HK from relatives of patients is encouraged as it may enhance accuracy of the diagnosis and provide a better appraisal of treatment progress.

Screening Methods for REM Sleep Behavior Disorder 189

American Sleep Disorders Association, Diagnostic Classification Steering Committee. (1997).

American Academy of Sleep Medicine. (2005) . The International Classification of Sleep

Boeve,BF., Ferman, TJ., Silber,MH., Smith, GE.(2002a). Validation of a Questionnaire for the Diagnosis of REM Sleep Behavior Disorder. *Neurology* 58 (Suppl 3): A509. Boeve,BF., Silber ,MH., Ferman, TJ., Smith, GE.(2002b). Validation of a questionnaire for the diagnosis of REM sleep behavior disorder. *Sleep* (Abstract Suppl): A 486. Boeve ,BF. (2010a). REM sleep behavior disorder: Updated review of the core features, the

Boeve, BF., Molano, JR., Ferman, TJ., Smith, GE., Lin, SC., Bieniek, K., Haidar, W.,

Manual. American Sleep Disorders Association, Rochester, MN.

The International Classification of Sleep Disorders, Revised: Diagnostic and Coding

Disorders: Diagnostic and Coding Manual. 2nd ed. American Academy of Sleep

REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies,and future directions. *Ann. N.Y. Acad. Sci.* 1184: 15-54. Boeve ,BF., Molano, J., Ferman ,T., Smith ,G., Bieniek, KF., Tippmann-Peikert ,M., Knopman

,D., Pankratz ,VS., Geda ,Y., Roberts ,R., Tangalos,E., Silber ,M., Petersen ,R. (2010b). Screening for REM Sleep Behavior Disorder in the Community-Dwelling Elderly: Validation of the Mayo Sleep Questionnaire in the Mayo Clinic Study of

Tippmann-Peikert, M., Knopman, DS., Graff-Radford, NR., Lucas, JA., Petersen, RC,. Silber, MH. (2011). Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in aging and dementia cohort. *Sleep Med* ,doi:

**8. References**

Medicine, Westchester, IL.

Aging. *Neurology* 74 ( Suppl 2): A432.

10.1016/j.sleep.2010.12.009.
